Health
Company Recalls Diabetes Drug Amid Concerns of Carcinogen Contamination
A drugmaker is recalling a product used to treat patients with Type 2 diabetes due to possible contamination with a potentially cancer-causing compound.
The Kansas City, Missouri-based Nostrum Laboratories announced this week that it is voluntary recalling a series of metformin HCl extended-release tablets, USP 750 mg, according to a recall posted by the Food and Drug Administration, CNN reported.
Testing show unacceptable levels of nitrosamine, or NDMA, in the recalled tablets, CNN reported.
The chemical NDMA, considered a possible carcinogen by the Environmental Protection Agency, has also been found in certain blood pressure drugs and antacid.
